What is in a name? Refined diagnostic criteria for prognostic assessment in myelodysplastic syndrome (MDS)

Leukemia Research

Volumn 28, Issue 6, 2004, Pages 543-544

  Deeg, H Joachim ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SURVIVAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; DISEASE COURSE; DISEASE SEVERITY; DYSPLASIA; EDITORIAL; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; LIFE EXPECTANCY; MYELODYSPLASTIC SYNDROME; NEPHROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ANEMIA, REFRACTORY; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RISK FACTORS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 2142722206     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.11.008     Document Type: Editorial

References (18)

1. Armitage J.O. Overview of rational and individualized therapeutic strategies for non-Hodgkin's lymphomas (review). Clin. Lymphoma. 3(Suppl. 1):2002;S5-S11
2. Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346:2002;1937
3. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A.G., Gralnick H.R., et al. The French-American-British (FAB) Co-Operative Group. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51:1982;189
4. Shetty V., Mundle S., Alvi S., Showel M., Broady-Robinson L., Dar S., et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk. Res. 20:1996;891
5. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting - Airlie House, Virginia, November 1997. J. Clin. Oncol. 17:1999;3835
6. Albitar M., Manshouri T., Shen Y., Liu D., Beran M., Kantarjian H.M., et al. Myelodysplastic syndrome is not merely "preleukemia" Blood. 100:2002;791
7. Cutler C., Lee S., Greenberg P., Deeg J., Antin J., Perez W., et al. A decision analysis of allogeneic stem cell transplantation for MDS: delayed transplantation for low risk MDS is associated with improved outcome. Blood. 100 (Part 1):2002;74a., 270 (abstract)
8. Anderson J.E., Appelbaum F.R., Fisher L.D., Schoch G., Shulman H., Anasetti C., et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood. 82:1993;677
9. Deeg H.J., Storer B., Slattery J.T., Anasetti C., Doney K.C., Hansen J.A., et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 100:2002;1201
10. Deeg H.J., Shulman H.M., Anderson J.E., Bryant E.M., Gooley T.A., Slattery J.T., et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood. 95:2000;1188
11. Appelbaum F.R., Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia. 12(Suppl 1):1998;S25-S29
12. Nevill T.J., Fung H.C., Shepherd J.D., Horsman D.E., Nantel S.H., Klingemann H.G., et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood. 92:1998;1910
13. Cilloni D., Gottardi E., Messa F., Fava M., Scaravaglio P., Bertini M., et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J. Clin. Oncol. 21:2003;1988
14. Wells D.A., Benesch M., Loken M.R., Vallejo C., Myerson D., Leisenring W.M., et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hemopoietic stem cell transplantation. Blood. 102:2003;394
15. Hofmann W.K., de Vos S., Komor M., Hoelzer D., Wachsman W., Koeffler H.P. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood. 100:2002;3553
16. Span L.F., Dar S.E., Shetty V., Mundle S.D., Broady-Robinson L., Alvi S., et al. Apparent expansion of CD34+ cells during the evolution of myelodysplastic syndromes to acute myeloid leukemia. Leukemia. 12:1998;1685
17. Bellamy W.T., Richter L., Sirjani D., Roxas C., Glinsmann-Gibson B., Frutiger Y., et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 97:2001;1427
18. Korkolopoulou P., Apostolidou E., Pavlopoulos P.M., Kavantzas N., Vyniou N., Thymara I., et al. Prognostic evaluation of the microvascular network in myelodysplastic syndromes. Leukemia. 15:2001;1369